Global pattern of trends in incidence, mortality, and mortality-to-incidence ratio rates related to liver cancer, 1990–2019: a longitudinal analysis based on the global burden of disease study

Abstract

Background Liver cancer (LC) is considered as one of the most dominant malignant tumors which ranked 4th and in terms of global mortality and incidence, respectively. This work aimed to investigate the global temporal trends in LC mortality-to-incidence ratio (MIR) and its components, with a particular focus on examining long-term effect of human development index (HDI) on these metrics in a 30-year follow-up. Methods The age-standardized LC incidence and mortality data were derived from the global burden of disease (GBD) study 2019. We first leveraged joinpoint piecewise linear regression analysis to ascertain time trends in LC incidence, mortality, and MIR complement [1-MIR] and the average annual percentage change (AAPC) of the rates over the period 1990–2019. Then, the association between the metrics and HDI was explored through longitudinal multilevel models (LMMs). Results The incidence rates paralleled the mortality rates worldwide and they had similar significant monotonic decrementing trends with AAPC values of − 1.10% (95% confidence interval (CI): − 1.40, − 0.90%) and − 1.40% (− 1.50, − 1.30%), respectively from 1990 to 2019. The [1-MIR] rates were around 0 and showed an increasing pattern from 1.70 to 8.10 per 100,000 people (AAPC, 4.90%) at the same period of time. Results from the LMMs displayed that the majority of the variation lies at the country level accounted for about 88% of the total variance. Moreover, our analysis supported that the HDI was negatively associated with either incidence or mortality over time (p < 0.05). Conclusions Our findings highlighted that the global long-term temporal trends of LC incidence and mortality decreased slightly during 1990–2019 which may reflect improved therapeutic strategies and public health interventions. Besides, the low rates of [1-MIR] revealed the five-year relative survival rate was poor implying LC is diagnosed late in its development. Thereby, the policymakers’ focus must be on early screening and detection of liver cancer.

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

“…[3] Men are affected approximately two to three times more than women, with higher incidence and mortality across most countries. [4] There are also notable racial and ethnic disparities in HCC, with a disproportionate burden of disease affecting American Indian, Hispanic, and Black persons more than non-Hispanic White persons. [5] In the United States, HCC incidence and mortality rates increased from 1970 to 2010, but incidence began to decrease in 2011, and mortality plateaued in 2013, with one study showing a subsequent ∼3% decrease per year.…”

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment

“…Hepatocellular carcinoma (HCC) is the most common histological type in primary liver cancer, which occurs predominantly in individuals with chronic liver disease or cirrhosis. HCC is the fourth leading cause of cancer-related death worldwide, and its incidence has been rising globally over the last 20 years ( 1 , 2 ). It has been expected to keep increasing until 2030 in some countries including the United States, and it has become the fourth of the most common malignancies in China ( 3 , 4 ).…”

“…Patients with early-stage HCC may be curable by receiving radical treatment, such as local ablation, surgical resection, or liver transplantation. However, a high recurrence rate still exists (5-year survival rate after surgery is only approximately 35%) ( 2 ). In addition, over one-half of HCC patients have already been at an advanced stage when diagnosed due to the lack of sensitive and specific diagnostic tools in the clinic.…”

WNK1–OSR1 Signaling Regulates Angiogenesis-Mediated Metastasis towards Developing a Combinatorial Anti-Cancer Strategy

“…Cancer is one of the leading causes of death globally and its incidence is still rising [ 1 ]. Liver cancer ranks fourth among cancers in terms of mortality and incidence [ 2 ], and there is a lack of effective systematic treatments for advanced-stage of liver cancer [ 3 ]. Effective treatment for liver cancer is an urgent unmet medical need.…”